Abeona Therapeutics (NASDAQ:ABEO) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.11), Zacks reports. The business had revenue of $1.71 million for the quarter, compared to analysts’ expectations of $1.02 million. Abeona Therapeutics had a negative net margin of 843.14% and a negative return on equity of 27.01%.

Shares of ABEO opened at $7.71 on Tuesday. Abeona Therapeutics has a twelve month low of $7.70 and a twelve month high of $22.00. The stock has a market cap of $448.75 million, a PE ratio of -11.68 and a beta of 1.77.

Several research firms have commented on ABEO. Cantor Fitzgerald set a $36.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Monday. BidaskClub downgraded shares of Abeona Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, November 8th. Zacks Investment Research raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 17th. HC Wainwright set a $30.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Friday, July 27th. Finally, ValuEngine raised shares of Abeona Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $25.90.

WARNING: “Abeona Therapeutics (ABEO) Issues Quarterly Earnings Results” was originally published by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2018/11/13/abeona-therapeutics-abeo-issues-quarterly-earnings-results.html.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Featured Story: Insider Trading – What You Need to Know

Earnings History for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.